Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1287-1292

  Park, Benjamin J ^a,d   Arthington Skaggs, Beth A ^a   Hajjeh, Rana A ^a   Iqbal, Naureen ^a   Ciblak, Meral A ^a   Lee Yang, Wendy ^a   Hairston, Mario D ^a   Phelan, Maureen ^a   Plikaytis, Brian D ^a   Sofair, Andre N ^b   Harrison, Lee H ^c   Fridkin, Scott K ^a   Warnock, David W ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ARTICLE; BLOOD SAMPLING; CANDIDA; CANDIDIASIS; CHROMOSOME BREAKAGE; EVALUATION; FUNGICIDAL ACTIVITY; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT FAILURE;

EID: 33645777826     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1287-1292.2006     Document Type: Article

References (17)

1. Antoniadou, A., H. A. Torres, R. E. Lewis, J. Thornby, G. P. Bodey, J. J. Tarrand, X. Y. Han, K. V. I. Rolston, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2003. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82:309-321.
2. Arendrup, M., B. Lundgren, I. M. Jensen, B. S. Hansen, and N. Frimodt-Moller. 2001. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J. Antimicrob. Chemother. 47:521-526.
3. Brandt, M. E., L. H. Harrison, M. Pass, A. N. Sofair, S. Huie, R. K. Li, C. J. Morrison, D. W. Warnock, and R. A. Hajjeh. 2000. Candida dubliniensis fungemia: the first four cases in North America. Emerg. Infect. Dis. 6:46-49.
4. Clancy, C. J., and M. H. Nguyen. 1999. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob. Agents Chemother. 43:1289-1290.
5. Conly, J., R. Rennie, J. Johnson, S. Farah, and L. Hellman. 1992. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J. Infect. Dis. 165:761-764.
6. Hajjeh, R. A., A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
7. Lozano-Chiu, M., P. W. Nelson, M. Lancaster, M. A. Pfaller, and J. H. Rex. 1997. Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B. J. Clin. Microbiol. 35:270-272.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologie response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
10. Nguyen, M. H., J. E. Peacock, D. C. Tanner, A. J. Morris, M. L. Nguyen, D. R. Snydman, M. M. Wagener, and V. L. Yu. 1995. Therapeutic approaches in patients with candidemia. Arch. Intern. Med. 155:2429-2435.
11. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
12. Peyron, F., A. Favel, A. Michel-Nguyen, M. Gilly, P. Regli, and A. Bolmstrom. 2001. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest. J. Clin. Microbiol. 39:339-342.
13. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
14. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
15. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb. 1995. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
16. Sterling, T. R., R. A. Gasser, and A. Ziegler. 1996. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 23:187-188.
17. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1997. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.